Imunon Inc Total Assets
Imunon Inc total assets. Based on the latest financial reports, Imunon Inc (IMNN) holds total assets worth $14.99 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Imunon Inc market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of Imunon Inc (1996–2025)
Total assets of Imunon Inc from 1996 to 2025. This chart illustrates how Imunon Inc's total assets have evolved over time, based on quarterly financial data. See Imunon Inc (IMNN) share price today for real-time trading data and today's change.
Imunon Inc - Asset Composition Analysis
Imunon Inc Total Assets Breakdown (December 2025)
Imunon Inc total assets breakdown as of December 2025. Imunon Inc's total assets of $14.99 Million consist of 87.3% current assets and 12.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 71.5% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1996–2025)
This chart illustrates how Imunon Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore IMNN net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Imunon Inc's current assets represent 87.3% of total assets in 2025, an increase from 7.6% in 1996.
- Cash Position: Cash and equivalents constituted 71.5% of total assets in 2025, up from 2.7% in 1996.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 1996.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Imunon Inc Competitors by Total Assets
Key competitors of Imunon Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Imunon Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.82 | 1.30 | 8.77 |
| Quick Ratio | 1.82 | 1.30 | 8.77 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.91 Million | $1.57 Million | $50.29 Million |
Imunon Inc - Advanced Valuation Insights
This section examines the relationship between Imunon Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.93 |
| Latest Market Cap to Assets Ratio | 0.41 |
| Asset Growth Rate (YoY) | 26.5% |
| Total Assets | $12.29 Million |
| Market Capitalization | $5.05 Million USD |
Valuation Analysis
Below Book Valuation: The market values Imunon Inc's assets below their book value (0.41x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Imunon Inc's assets grew by 26.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Imunon Inc (1996–2025)
The table below shows the annual total assets of Imunon Inc from 1996 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $12.29 Million | +26.45% |
| 2024-12-31 | $9.72 Million | -55.67% |
| 2023-12-31 | $21.92 Million | -50.16% |
| 2022-12-31 | $43.98 Million | -40.61% |
| 2021-12-31 | $74.05 Million | +97.31% |
| 2020-12-31 | $37.53 Million | -1.96% |
| 2019-12-31 | $38.28 Million | -18.31% |
| 2018-12-31 | $46.86 Million | -1.39% |
| 2017-12-31 | $47.51 Million | +54.02% |
| 2016-12-31 | $30.85 Million | -37.08% |
| 2015-12-31 | $49.03 Million | -26.49% |
| 2014-12-31 | $66.69 Million | +46.03% |
| 2013-12-31 | $45.67 Million | +80.10% |
| 2012-12-31 | $25.36 Million | -22.33% |
| 2011-12-31 | $32.65 Million | +1192.92% |
| 2010-12-31 | $2.53 Million | -82.94% |
| 2009-12-31 | $14.81 Million | -37.50% |
| 2008-12-31 | $23.69 Million | -39.32% |
| 2007-12-31 | $39.04 Million | +106.23% |
| 2006-12-31 | $18.93 Million | +18.98% |
| 2005-12-31 | $15.91 Million | -6.70% |
| 2004-12-31 | $17.05 Million | +18.09% |
| 2003-12-31 | $14.44 Million | +530.16% |
| 2002-12-31 | $2.29 Million | -22.50% |
| 2001-12-31 | $2.96 Million | -67.57% |
| 2000-12-31 | $9.12 Million | +469.86% |
| 1999-12-31 | $1.60 Million | +383.77% |
| 1998-12-31 | $330.74K | -59.82% |
| 1997-12-31 | $823.21K | -91.17% |
| 1996-12-31 | $9.32 Million | -- |
About Imunon Inc
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase fo… Read more